DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Cefazolin Pharmacokinetics: Elimination Clearance in Neonates

Information source: Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Prophylaxis

Intervention: Cefazolin (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Universitaire Ziekenhuizen Leuven

Official(s) and/or principal investigator(s):
Karel Allegaert, MD PhD, Principal Investigator, Affiliation: University Hospitals Leuven

Summary

To document cefazolin disposition (concentration/time profile, protein binding, metabolism, renal elimination characteristics) and its covariates in neonates following intravenous administration of the drug at induction of anesthesia, prior to an invasive procedure To evaluate if optimalisation of cefazolin dose regimen during neonatal life is needed

Clinical Details

Official title: Cefazolin Pharmacokinetics: Elimination Clearance in Neonates

Study design: Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Primary outcome: Pharmacokinetics of iv cefazolin in neonates

Secondary outcome: Optimalisation of cefazolin dose regimen during neonatal life

Detailed description: Prospective, single-center, open label study on the pharmacokinetics of iv cefazolin administration in neonates admitted in the neonatal intensive care unit, University Hospitals Leuven, Belgium. Patients will be included after signed informed consent of the parents. Our aim is to include 40 neonates. Cefazolin has been selected for this study as it is routinely administered in neonates undergoing invasive procedures in our unit. At this stage, we only have the intention to document pharmacokinetics and covariates based on the current clinical practice and therefore will not interfere with either clinical indication, or with dosing as prescribed by the attending physician. Drug administration and collection of samples will be obtained to the current clinical and nursing standard procedures. Routine clinical care for scheduled invasive procedures in neonates in our unit is intravenous administration of cefazolin as follows:

- 50 mg/kg, 3 times a day

- an extra dose of 50mg/kg is given after 3 hours for operations longer than 3 h

- each time one dose/day is excluded for neonates with body weight <2000 g and postnatal

age (PNA) <7 days,

- for invasive operations (e. g. open-heart surgery, laparotomy) the prophylactic

administration of cefazolin may be continued for 3-5 days following the completion of surgery. The antibiotic agent should be administered 30 minutes to 1 hour prior to the start of surgery so that adequate antibiotic levels. Cefazolin is administered to the neonate, through a peripherally inserted venous catheter, during 30 minutes. Blood will be collected in heparinised tubes through an indwelling arterial line, or deep venous access, always when other routine blood samples are collected for clinical purposes (pO2, pCO2, pH). Urine samples will be collected through a bladder catheter in patients in whom a bladder catheter is available for clinical indications. Pharmacokinetic analysis A population pharmacokinetics approach will be used, hereby comparing the data on PK already reported in adults or older children and the newly collected data during neonatal life.

Eligibility

Minimum age: N/A. Maximum age: 28 Days. Gender(s): Both.

Criteria:

Inclusion Criteria:

- signed parental informed written consent

- neonates to whom cefazolin is administered by intravenous route for clinical

indications (invasive procedure) Exclusion Criteria:

- known cefazolin intolerance

Locations and Contacts

Additional Information

Starting date: February 2011
Last updated: December 12, 2011

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017